ArticleCureus2025
Benefits of an Exclusive Human Milk Diet in a Very Preterm Infant With an Ileostomy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mother's milk (MOM) provides numerous benefits for very preterm infants; however, it requires fortification to achieve appropriate nutrition intake. Although cow milk-based human milk fortifier (CMHMF) is widely used in Japan, it poses a risk of fatty acid calcium formation in infants with ileostomy. An exclusive human milk diet (EHMD) uses only human milk products to fortify MOM or donor human milk using a human milk-based human milk fortifier. Compared to CMHMF, EHMD reduces feeding intolerance and necrotizing enterocolitis in premature infants and may be safely used in infants with an ileostomy. However, specific studies addressing the nutritional effects of EHMD in these patients are lacking. This case report discusses the potential benefits of an EHMD in an infant undergoing ileostomy. The male infant, weighing 742 g, was delivered by emergency cesarean section at the postmenstrual age of 26 weeks and three days. On day eight of life, the patient underwent intestinal resection and anastomosis for a localized intestinal perforation. CMHMF could not be used because of the risk of fatty acid calcium stone formation. Given concerns regarding malnutrition, the case was administered an EHMD. Following the introduction of EHMD, his weight gain improved from 5 g/day to 17 g/day, and his z-score improved from -0.8 standard deviation (SD) to +0.3 SD. No adverse events were observed. It is suspected that the improvement in the anthropometric data was attributable to the establishment and maintenance of full feeding volumes alongside the EHMD, which ensured adequate nutrition and increased nutritional intake. This case suggests that EHMD may be a safe and effective nutritional strategy to promote optimal growth and development in infants undergoing abdominal surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.